The collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and
This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer. Chimeric Antigen Receptor T-cell
The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose
The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for
The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide. Harbour BioMed CEO
Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of
AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly experienced pharma industry veterans led by Pete Finan, former head
Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug
Located in Boston’s booming biotech and pharmaceutical hub, PCI Synthesis offers its customers a wide range of services, including process research and early stage development as well as
The submission uses a rare disease priority review voucher, which designates the BLA for an expedited eight-month review by the FDA instead of the standard 12-month review. Alexion
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.